{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:39:44Z","timestamp":1792532384713,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["FNBr"],"award-info":[{"award-number":["FNBr"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["65269705"],"award-info":[{"award-number":["65269705"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-03-00562"],"award-info":[{"award-number":["NV19-03-00562"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU20-03-00240"],"award-info":[{"award-number":["NU20-03-00240"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV16-34083A"],"award-info":[{"award-number":["NV16-34083A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MUNI\/A\/1764\/2024"],"award-info":[{"award-number":["MUNI\/A\/1764\/2024"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LM2023049"],"award-info":[{"award-number":["LM2023049"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018706","name":"HORIZON EUROPE Widening participation and spreading excellence","doi-asserted-by":"publisher","award":["101059788"],"award-info":[{"award-number":["101059788"]}],"id":[{"id":"10.13039\/100018706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002846","name":"Nadacn\u00ed Fond Detsk\u00e9 Onkologie Krtek","doi-asserted-by":"publisher","award":["COEF"],"award-info":[{"award-number":["COEF"]}],"id":[{"id":"10.13039\/501100002846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"DOI":"10.1007\/s40487-026-00468-1","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:37:59Z","timestamp":1792485479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal Combination Treatment in a Patient-Centered Approach is Associated with Improved Outcome in Relapsed\/Refractory Sarcomas in Children: A Comparative Single-Institution Real-World Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-8386","authenticated-orcid":false,"given":"Michal","family":"Kyr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Polaskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitezslav","family":"Dusek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Vejmelkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Kuttnerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Tinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Merta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Pokorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Palova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Neradil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Veselska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jezova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Slaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalibor","family":"Valik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Sterba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"468_CR1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41591-022-01856-6","volume":"28","author":"AJ Church","year":"2022","unstructured":"Church AJ, et\u00a0al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022;28:1581\u20139.","journal-title":"Nat Med"},{"key":"468_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, et\u00a0al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2020;21:121\u201333.","journal-title":"Lancet Oncol"},{"key":"468_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00644","volume":"9","author":"M Kyr","year":"2019","unstructured":"Kyr M, et\u00a0al. Individualization of treatment improves the survival of children with high-risk solid tumors: comparative patient series analysis in a real-life scenario. Front Oncol. 2019;9:644.","journal-title":"Front Oncol"},{"key":"468_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102161","volume":"104","author":"P Pokorna","year":"2024","unstructured":"Pokorna P, et\u00a0al. Real-world performance of integrative clinical genomics in pediatric precision oncology. Lab Invest. 2024;104:102161.","journal-title":"Lab Invest"},{"key":"468_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000336483","volume":"82","author":"D Zapletalova","year":"2012","unstructured":"Zapletalova D, et\u00a0al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology. 2012;82:249\u201360.","journal-title":"Oncology"},{"key":"468_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00930","volume":"9","author":"J Neradil","year":"2019","unstructured":"Neradil J, et\u00a0al. Phospho-protein arrays as effective tools for screening possible targets for kinase inhibitors and their use in precision pediatric oncology. Front Oncol. 2019;9:930.","journal-title":"Front Oncol"},{"key":"468_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215428","volume":"13","author":"M Kyr","year":"2021","unstructured":"Kyr M, Svobodnik A, Stepanova R, Hejnova R. N-of-1 trials in pediatric oncology: from a population-based approach to personalized medicine\u2014A review. Cancers. 2021;13:5428.","journal-title":"Cancers"},{"key":"468_CR8","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/ijc.35062","volume":"155","author":"M Kyr","year":"2024","unstructured":"Kyr M, et\u00a0al. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients. Int J Cancer. 2024;155:1443\u201354.","journal-title":"Int J Cancer"},{"key":"468_CR9","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff DD, et\u00a0al. Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28:4877\u201383.","journal-title":"J Clin Oncol"},{"key":"468_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","volume":"68","author":"RL Prentice","year":"1981","unstructured":"Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373\u20139.","journal-title":"Biometrika"},{"key":"468_CR11","unstructured":"R Core Team (2022). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"468_CR12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","volume":"26","author":"M Wong","year":"2020","unstructured":"Wong M, et\u00a0al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26:1742\u201353.","journal-title":"Nat Med"},{"key":"468_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/ijms19030739","volume":"19","author":"K Nakano","year":"2018","unstructured":"Nakano K, Takahashi S. Current molecular targeted therapies for bone and soft tissue sarcomas. IJMS. 2018;19:739.","journal-title":"IJMS"},{"key":"468_CR14","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1002\/sim.2434","volume":"25","author":"JM Box-Steffensmeier","year":"2006","unstructured":"Box-Steffensmeier JM, De Boef S. Repeated events survival models: the conditional frailty model. Stat Med. 2006;25:3518\u201333.","journal-title":"Stat Med"},{"key":"468_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15154012","volume":"15","author":"G Bisogno","year":"2023","unstructured":"Bisogno G, et\u00a0al. Maintenance chemotherapy for patients with rhabdomyosarcoma. Cancers. 2023;15:4012.","journal-title":"Cancers"},{"key":"468_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","volume":"7","author":"E Zsiros","year":"2021","unstructured":"Zsiros E, et\u00a0al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2021;7:78.","journal-title":"JAMA Oncol"},{"key":"468_CR17","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1001\/jamaoncol.2017.0324","volume":"3","author":"R Pramanik","year":"2017","unstructured":"Pramanik R, et\u00a0al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol. 2017;3:1222.","journal-title":"JAMA Oncol"},{"key":"468_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3747\/co.23.2873","volume":"23","author":"AM Ali","year":"2016","unstructured":"Ali AM, El-Sayed MI. Metronomic chemotherapy and radiotherapy as salvage treatment in refractory or relapsed pediatric solid tumours. Curr Oncol. 2016;23:253\u20139.","journal-title":"Curr Oncol"},{"key":"468_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864790","volume":"12","author":"J Bodea","year":"2022","unstructured":"Bodea J, Caldwell KJ, Federico SM. Bevacizumab, with sorafenib and cyclophosphamide provides clinical benefit for recurrent or refractory osseous sarcomas in children and young adults. Front Oncol. 2022;12:864790.","journal-title":"Front Oncol"},{"key":"468_CR20","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-09-1106","volume":"69","author":"H Tanaka","year":"2009","unstructured":"Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009;69:6987\u201394.","journal-title":"Cancer Res"},{"key":"468_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007253","volume":"11","author":"Y-N Wang","year":"2023","unstructured":"Wang Y-N, et\u00a0al. Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response. J Immunother Cancer. 2023;11:e007253.","journal-title":"J Immunother Cancer"},{"key":"468_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216254","volume":"11","author":"M Banchi","year":"2022","unstructured":"Banchi M, Fini E, Crucitta S, Bocci G. Metronomic chemotherapy in pediatric oncology: from preclinical evidence to clinical studies. J Clin Med. 2022;11:6254.","journal-title":"J Clin Med"},{"key":"468_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/jamaoncol.2024.0194","volume":"10","author":"A Tibau","year":"2024","unstructured":"Tibau A, Hwang TJ, Molto C, Avorn J, Kesselheim AS. Clinical value of molecular targets and FDA-approved genome-targeted cancer therapies. JAMA Oncol. 2024;10:634.","journal-title":"JAMA Oncol"},{"key":"468_CR24","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, et\u00a0al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879\u201386.","journal-title":"Lancet"},{"key":"468_CR25","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, et\u00a0al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.","journal-title":"Lancet"},{"key":"468_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, et\u00a0al. Gastrointestinal stromal tumours: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:20\u201333.","journal-title":"Ann Oncol"},{"key":"468_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103006","volume":"9","author":"D Orbach","year":"2024","unstructured":"Orbach D, et\u00a0al. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study). ESMO Open. 2024;9:103006.","journal-title":"ESMO Open"},{"key":"468_CR28","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/ijc.25843","volume":"129","author":"ST Mahmood","year":"2011","unstructured":"Mahmood ST, et\u00a0al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011;129:1963\u20139.","journal-title":"Int J Cancer"},{"key":"468_CR29","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1245\/s10434-015-4680-3","volume":"22","author":"J Jakob","year":"2015","unstructured":"Jakob J, et\u00a0al. Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma. Ann Surg Oncol. 2015;22:2839\u201345.","journal-title":"Ann Surg Oncol"},{"key":"468_CR30","doi-asserted-by":"crossref","unstructured":"Dong, S. et\u00a0al. Metformin sensitises osteosarcoma to chemotherapy via the IGF-1R\/miR-610\/FEN1 pathway. Eur J Histochem 67, (2023).","DOI":"10.4081\/ejh.2023.3612"},{"key":"468_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083832","volume":"8","author":"C Garofalo","year":"2013","unstructured":"Garofalo C, et\u00a0al. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. PLoS ONE. 2013;8:e83832.","journal-title":"PLoS ONE"},{"key":"468_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/CORR.0000000000002045","volume":"480","author":"ID Hutchinson","year":"2022","unstructured":"Hutchinson ID, Ata A, DiCaprio MR. Is metformin use associated with prolonged overall survival in patients with soft tissue sarcoma? A SEER-Medicare study. Clin Orthop Relat Res. 2022;480:735\u201344.","journal-title":"Clin Orthop Relat Res"},{"key":"468_CR33","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1002\/cam4.5297","volume":"12","author":"JL Metts","year":"2023","unstructured":"Metts JL, et\u00a0al. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: a report from the national pediatric cancer foundation. Cancer Med. 2023;12:4270\u201381.","journal-title":"Cancer Med"},{"key":"468_CR34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.4161\/cbt.28163","volume":"15","author":"S Tavallai","year":"2014","unstructured":"Tavallai S, Hamed HA, Grant S, Poklepovic A, Dent P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biol Ther. 2014;15:578\u201385.","journal-title":"Cancer Biol Ther"},{"key":"468_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10020053","volume":"10","author":"V Monga","year":"2018","unstructured":"Monga V, et\u00a0al. A phase I\/II study targeting angiogenesis using bevacizumab combined with chemotherapy and a histone deacetylase inhibitor (valproic acid) in advanced sarcomas. Cancers. 2018;10:53.","journal-title":"Cancers"},{"key":"468_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1166\/jpsp.2014.1013","volume":"1","author":"S Kayarthodi","year":"2014","unstructured":"Kayarthodi S, et\u00a0al. Anti-epileptic drug targets Ewing sarcoma. Journal of Pharmaceutical Sciences and Pharmacology. 2014;1:87\u2013100.","journal-title":"Journal of Pharmaceutical Sciences and Pharmacology"},{"key":"468_CR37","doi-asserted-by":"publisher","first-page":"e948","DOI":"10.1097\/MPH.0000000000002488","volume":"44","author":"NJ Spasov","year":"2022","unstructured":"Spasov NJ, et\u00a0al. First-line anti-GD2 therapy combined with consolidation chemotherapy in 3 patients with newly diagnosed metastatic Ewing sarcoma or Ewing-like sarcoma. J Pediatr Hematol Oncol. 2022;44:e948\u201353.","journal-title":"J Pediatr Hematol Oncol"},{"key":"468_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/pbc.22693","volume":"56","author":"T Simon","year":"2011","unstructured":"Simon T, et\u00a0al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials: outcome of relapsed. High-Risk Neuroblastoma Pediatr Blood Cancer. 2011;56:578\u201383.","journal-title":"High-Risk Neuroblastoma Pediatr Blood Cancer"},{"key":"468_CR39","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1200\/JCO.2007.14.7207","volume":"26","author":"O Oberlin","year":"2008","unstructured":"Oberlin O, et\u00a0al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. JCO. 2008;26:2384\u20139.","journal-title":"JCO"},{"key":"468_CR40","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2005.05.105","volume":"23","author":"LM Barker","year":"2005","unstructured":"Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing\u2019s sarcoma family of tumors. JCO. 2005;23:4354\u201362.","journal-title":"JCO"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00468-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00468-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00468-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:02:11Z","timestamp":1792530131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00468-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":40,"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00468-1","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michal Kyr, Kristyna Polaskova, Peter Mudry, Vitezslav Dusek, Klara Vejmelkova, Zuzana Kuttnerova, Pavel Tinka, Tomas Merta, Petra Pokorna, Hana Palova, Jakub Neradil, Renata Veselska, Marta Jezova, Ondrej Slaby, Dalibor Valik, and Jaroslav Sterba declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki of 1964 and its later amendments. All patients or their legal guardians signed an informed consent. The study was approved by the institutional review board 13-160322\/EK.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}